
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Attenuon, LLC, San Diego, California and 2 D.E. Shaw Research and Development, LLC, New York, New York
Requests for reprints: Andrew P. Mazar, Attenuon, LLC, 11535 Sorrento Valley Road, San Diego, CA 92121. Phone: 858-622-0510; Fax: 858-622-0517; E-mail: mazar{at}attenuon.com.
Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.
Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.
Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic.
Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
This article has been cited by other articles:
![]() |
M. L. Turski and D. J. Thiele New Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease J. Biol. Chem., January 9, 2009; 284(2): 717 - 721. [Full Text] [PDF] |
||||
![]() |
S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt, S. Joel, F. Donate, C. Hayward, S. Reich, et al. Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7526 - 7534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Juarez, M. Manuia, M. E. Burnett, O. Betancourt, B. Boivin, D. E. Shaw, N. K. Tonks, A. P. Mazar, and F. Donate Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling PNAS, May 20, 2008; 105(20): 7147 - 7152. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Fruehauf and F. L. Meyskens Jr. Reactive Oxygen Species: A Breath of Life or Death? Clin. Cancer Res., February 1, 2007; 13(3): 789 - 794. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |